ZymoGenetics ZGEN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymoGenetics ZGEN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (201)	12/16/2009 10:21:39 AM
From: tuck	of 210

I don't recall them even hinting about that. From the original PR: >>In the United States, Bayer HealthCare will co-promote rThrombin with ZymoGenetics for a three-year period beginning at launch. Bayer HealthCare will leverage its strong surgery-focused field force of sales representatives and medical science liaisons for the co-promotion effort, aimed toward establishing a significant U.S. market share as well as expanding the size of the U.S. thrombin market. ZymoGenetics will compensate Bayer HealthCare for its efforts in the U.S. by paying a tiered commission of up to 20% on U.S. sales and up to $20 million in sales bonus payments upon achievement of certain U.S. sales levels. For two years following the end of the co-promotion period, ZymoGenetics will pay Bayer HealthCare a sales commission at a reduced rate, subject to an annual maximum. For all sales outside the U.S., Bayer HealthCare will pay ZymoGenetics milestone payments and tiered royalties based on annual sales levels. Bayer HealthCare will retain rights to market rThrombin outside the United States indefinitely.<< Would it mirror the U.S. part of the deal? Probably not as generous, since the rights are indefinite? Beats me. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next